MAFP - Clinical: Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum

Test Catalog

Test Name

Test ID: MAFP    
Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Prenatal screening for open neural tube defect

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test


Alpha-fetoprotein (AFP) is a fetal protein that is initially produced in the fetal yolk sac and liver. A small amount also is produced by the gastrointestinal tract. By the end of the first trimester, nearly all of the AFP is produced by the fetal liver. The concentration of AFP peaks in fetal serum between 10 to 13 weeks. Fetal AFP diffuses across the placental barrier into the maternal circulation. A small amount also is transported from the amniotic cavity.


The AFP concentration in maternal serum rises throughout pregnancy, from the nonpregnancy level of 0.20 ng/mL to about 250 ng/mL at 32 weeks gestation. If the fetus has an open neural tube defect (NTD), AFP is thought to leak directly into the amniotic fluid causing unexpectedly high concentrations of AFP. Subsequently, the AFP reaches the maternal circulation; thus producing elevated serum levels. Other fetal abnormalities such as omphalocele, gastroschisis, congenital renal disease, esophageal atresia, and other fetal distress situations such as threatened abortion and fetal demise also may show AFP elevations. Increased maternal serum AFP values also may be seen in multiple pregnancies and in unaffected singleton pregnancies in which the gestational age has been underestimated.


Lower maternal serum AFP values have been associated with an increased risk for genetic conditions such as trisomy 21 (Down syndrome) and trisomy 18. Risks for these syndrome disorders are only provided with the use of multiple marker screening (QUAD / Quad Screen [Second Trimester] Maternal, Serum).


Measurement of maternal serum AFP values is a standard tool used in obstetrical care to identify pregnancies that may have an increased risk for NTD. The screen is performed by measuring AFP in maternal serum and comparing this value to the median AFP value in an unaffected population to obtain a multiple of the median (MoM). The laboratory has established a MoM cutoff of 2.5 MoM, which classifies each screen as either screen-positive or screen-negative. A screen-positive result indicates that the value obtained exceeds the established cutoff. A positive screen does not provide a diagnosis, but indicates that further evaluation should be considered.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.


An AFP multiple of the median (MoM) <2.5 is reported as screen negative. AFP MoMs > or =2.5 (singleton and twin pregnancies) are reported as screen positive.


An interpretive report will be provided.

Interpretation Provides information to assist in interpretation of the test results

Neural tube defects (NTD):

A screen-negative result indicates that the calculated alpha-fetoprotein (AFP) multiple of the median (MoM) falls below the established cutoff of 2.50 MoM. A negative screen does not guarantee the absence of NTDs.


A screen-positive result indicates that the calculated AFP MoM is > or =2.50 MoM and may indicate an increased risk for open NTDs. The actual risk depends on the level of AFP and the individual's pre-test risk of having a child with NTD based on family history, geographical location, maternal conditions such as diabetes and epilepsy, and use of folate prior to conception. A screen-positive result does not infer a definitive diagnosis of a NTD, but indicates that further evaluation should be considered. Approximately 80% of pregnancies affected with an open NTD have elevated AFP MoM values >2.5.


Follow up:

Upon receiving maternal serum screening results, all information used in the risk calculation should be reviewed for accuracy (ie, weight, diabetic status, gestational dating, etc.). If any information is incorrect the laboratory should be contacted for a recalculation of the estimated risks.


Screen-negative results typically do not warrant further evaluation.


Ultrasound is recommended to confirm dates for NTD screen-positive results. If ultrasound yields new dates that differ by at least 7 days, a recalculation should be considered. If dates are confirmed, high-resolution ultrasound and amniocentesis (including amniotic fluid AFP and acetylcholinesterase measurements for NTDs) are typically offered.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Race, weight, multiple fetus pregnancy, and insulin-dependent diabetes (IDD) may affect marker concentrations. Black mothers tend to have higher alpha-fetoprotein (AFP) levels but lower risk of neural tube defects (NTDs) and are assigned to a separate AFP median set. Multiple of the medians (MoMs) are adjusted for maternal weight (to account for dilution effects in heavier mothers). The AFP is adjusted upward in IDD to account for lower values in diabetic pregnancies.


The screen results are dependent on accurate information for gestation, race, insulin dependent diabetes, and weight. Inaccurate information can lead to significant alterations in the estimated risk. In particular, erroneous assessment of gestational age can result in false-positive or false-negative screen results. Because of its increased accuracy, we therefore recommend determination of gestational age by ultrasound, rather than by maternal dates alone when possible.


A screen-negative result does not guarantee the absence of fetal defects. A screen-positive result does not provide a diagnosis, but indicates that further diagnostic testing should be considered (an unaffected fetus may have screen-positive result for unknown reasons).


Valid measurements of AFP in maternal serum cannot be made after amniocentesis.


Triplet and higher multiple pregnancies cannot be interpreted.


Each center offering maternal serum screening to patients should establish a standard screening protocol, which provides pre- and post-screening education and appropriate follow-up for screen-positive results.

Clinical Reference Recommendations for in-depth reading of a clinical nature

Christensen RL, Rea MR, Kessler G, et al: Implementation of a screening program for diagnosing open neural tube defects: selection, evaluation, and utilization of alpha-fetoprotein methodology. Clin Chem 1986;32:1812-1817

Special Instructions and Forms Library of PDFs including pertinent information and consent forms, specimen collection and preparation information, test algorithms, and other information pertinent to test